Research in IMO
Ongoing projects
iPS cells as a study tool and model to implement the CRISPR-Cas system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
BST- Cordó umbilical
Evaluation of the effectiveness and security of umbilical cord blood eyedrops for the treatment of neurotrophic keratitis.
XPLORE
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration
Project history
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
IRIS II
Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy.